Innogenetics Overview

  • Year Founded
  • 1985

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 466

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $112M

  • Investors
  • 1

Innogenetics General Information

Description

Operator of a biotechnological company dedicated to improving therapy management and patient health. The company develops and markets diagnostic assays with a focus on molecular diagnostics and multiparameter testing.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Technologiepark 6
  • 9052 Ghent
  • Belgium
+32 09
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Vertical(s)
Corporate Office
  • Technologiepark 6
  • 9052 Ghent
  • Belgium
+32 09

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innogenetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 24-Sep-2010 $112M Completed Generating Revenue
11. PIPE 20-Oct-2008 Completed Generating Revenue
10. Merger/Acquisition 05-Sep-2008 Completed Generating Revenue
9. PIPE 01-Mar-2007 Completed Generating Revenue
8. PIPE 19-Oct-2005 Completed Generating Revenue
7. PIPE 01-Mar-2005 Completed Generating Revenue
6. PIPE 10-Dec-2003 Completed Generating Revenue
5. PIPE 15-Mar-2001 Completed Generating Revenue
4. PIPE 05-Dec-1997 $35.5M $83.4M Completed Generating Revenue
3. IPO 28-Nov-1996 $47.9M $47.9M Completed Generating Revenue
To view Innogenetics’s complete valuation and funding history, request access »

Innogenetics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Innogenetics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bayer Corporation Minority
Bio Analytical Research Corporation Corporation Minority
Biovest (Belgium) Venture Capital Minority
CRI BVBA Corporation Minority
Capricorn Partners Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Innogenetics Investments (2)

Innogenetics’s most recent deal was a Later Stage VC with CellTran for . The deal was made on 24-Aug-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CellTran 24-Aug-2007 Later Stage VC Drug Discovery
Cepheid 30-Nov-1998 Early Stage VC Diagnostic Equipment
To view Innogenetics’s complete investments history, request access »

Innogenetics FAQs

  • When was Innogenetics founded?

    Innogenetics was founded in 1985.

  • Where is Innogenetics headquartered?

    Innogenetics is headquartered in Ghent, Belgium.

  • What is the size of Innogenetics?

    Innogenetics has 466 total employees.

  • What industry is Innogenetics in?

    Innogenetics’s primary industry is Biotechnology.

  • Is Innogenetics a private or public company?

    Innogenetics is a Private company.

  • What is the current valuation of Innogenetics?

    The current valuation of Innogenetics is .

  • What is Innogenetics’s current revenue?

    The current revenue for Innogenetics is .

  • How much funding has Innogenetics raised over time?

    Innogenetics has raised $216M.

  • Who are Innogenetics’s investors?

    Bayer, Bio Analytical Research Corporation, Biovest (Belgium), CRI BVBA, and Capricorn Partners are 5 of 8 investors who have invested in Innogenetics.

  • When was Innogenetics acquired?

    Innogenetics was acquired on 24-Sep-2010.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »